National Survey on Dyslipidemic Patients (PRYSME)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: June 18, 2008
Last updated: August 4, 2009
Last verified: August 2009

The purpose of this observational study is to describe the time to lipid-lowering drug implementation in the management of dyslipidemic patients, according to the cardiovascular risk level.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Survey on Time to Lipid-lowering Drug Implementation on Dyslipidemic Patients in General Practice.

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • time to lipid-lowering drug implementation (immediately, treatment within a period 0-3 month and > 3 month, according to the cardiovascular risk level, (0 risk factor, 1 risk factor, 2 risk factors, ≥ 3 risk factors, secondary prevention). [ Time Frame: Once ] [ Designated as safety issue: No ]

Enrollment: 3655
Study Start Date: June 2008
Study Completion Date: January 2009

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

First three consecutive dyslipidemic patients seen by GP


Inclusion Criteria:

  • Diagnosis of dyslipemia made less than 2 years
  • Treated by a lipid-lowering drug
  • Agree to take part in the survey

Exclusion Criteria:

  • Patient included in a clinical trial
  Contacts and Locations
Please refer to this study by its identifier: NCT00701402

  Show 1207 Study Locations
Sponsors and Collaborators
Study Director: Alain Castaigne AstraZeneca
  More Information

No publications provided

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals Identifier: NCT00701402     History of Changes
Other Study ID Numbers: NIS-CFR-DUM-2007/9
Study First Received: June 18, 2008
Last Updated: August 4, 2009
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
time to lipid-lowering drug implementation
dyslipidemic patients

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Lipid Regulating Agents
Therapeutic Uses processed this record on April 15, 2014